GlassScriptPhysician profile
Scheena Shirika Williams
NPI 1467110486
$6,958.26
in general payments reported to CMS, 2019-2025
25 companies · $3,059 in 2025
The $3,059 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.67 · 2022: $1,667 · 2023: $2,084 · 2024: $119 · 2025: $3,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,262.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $863.97 | 2022-2025 | Caplyta |
| Alkermes, INC. | $847.92 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $460.25 | 2022-2025 | Azstarys |
| Abbvie INC. | $421.21 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $419.48 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $417.55 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lundbeck LLC | $398.60 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $397.65 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $364.61 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $333.64 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $314.56 | 2022-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $259.53 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $233.23 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $205.14 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $158.30 | 2022-2025 | Fanapt, Hetlioz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $156.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $144.25 | 2023 | Qelbree |
| Validus Pharmaceuticals LLC | $131.44 | 2022-2025 | Equetro, Equetro |
| Neos Therapeutics, LP | $116.53 | 2022 | |
| Bausch Health US, LLC | $92.01 | 2022 | |
| Ironshore Pharmaceuticals INC. | $85.98 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $58.56 | 2023 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $37.00 | 2023 | Quviviq |
| Orexo US, INC. | $21.09 | 2022 | |
| Sage Therapeutics, LLC | $19.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scheena Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.